📣 VC round data is live. Check it out!
- Public Comps
- Daxor
Daxor Valuation Multiples
Discover revenue and EBITDA valuation multiples for Daxor and similar public comparables like Pentixapharm Holding, Sensus Healthcare, Tobii, HeartBeam and more.
Daxor Overview
About Daxor
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
Founded
1971
HQ

Employees
12
Website
Financials (LTM)
EV
$61M
Valuation Multiples
Start free trialDaxor Financials
Daxor reported last 12-month revenue of $9M.
In the same LTM period, Daxor generated $6M in gross profit and had net loss of ($633K).
Revenue (LTM)
Daxor P&L
In the most recent fiscal year, Daxor reported revenue of $10M and net income of $9M.
Daxor is profitable as of last fiscal year, with net margin of 89%.
Financial data powered by Morningstar, Inc.
Daxor Stock Performance
Daxor has current market cap of $61M, and enterprise value of $61M.
Market Cap Evolution
Daxor's stock price is $10.50.
Daxor share price decreased by 2.8% in the last 30 days, and increased by 29.7% in the last year.
Daxor has an EPS (earnings per share) of $1.57.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $61M | $61M | 0.0% | -2.8% | -11.5% | 29.7% | $1.57 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialDaxor Valuation Multiples
Daxor trades at 7.1x EV/Revenue multiple.
EV / Revenue (LTM)
Daxor Financial Valuation Multiples
As of May 15, 2026, Daxor has market cap of $61M and EV of $61M.
Daxor has a P/E ratio of (96.7x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Daxor Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Daxor Margins & Growth Rates
Daxor grew revenue by 15% but net profit decreased by 113% in the last fiscal year.
In the most recent fiscal year, Daxor reported net margin of 89%.
Daxor Margins
Daxor Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Daxor Operational KPIs
Daxor's revenue per employee in the last FY averaged $0.9M, while opex per employee averaged $0.1M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Daxor Competitors
Daxor competitors include Pentixapharm Holding, Sensus Healthcare, Tobii, HeartBeam, Pangaea Oncology, SMAIO, BATM Advanced Communications, Pulmonx, Gentian Diagnostics and Xtant Medical.
Most Daxor public comparables operate across Medical Devices, Laboratory Services, HealthTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 503.6x | — | (3.0x) | — | |||
| 1.5x | 1.6x | (4.3x) | (4.5x) | |||
| 1.2x | 1.3x | 3.4x | 4.3x | |||
| — | 73.1x | (2.6x) | — | |||
| 4.0x | — | (61.4x) | — | |||
| 5.2x | 4.7x | (54.0x) | (54.5x) | |||
| 0.4x | 0.5x | 2.7x | 3.9x | |||
| 0.6x | 0.6x | (1.5x) | (1.6x) | |||
This data is available for Pro users. Sign up to see all Daxor competitors and their valuation data. Start Free Trial | ||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Daxor
| When was Daxor founded? | Daxor was founded in 1971. |
| Where is Daxor headquartered? | Daxor is headquartered in United States. |
| How many employees does Daxor have? | As of today, Daxor has over 12 employees. |
| Who is the CEO of Daxor? | Daxor's CEO is Michael R. Feldschuh. |
| Is Daxor publicly listed? | Yes, Daxor is a public company listed on Nasdaq. |
| What is the stock symbol of Daxor? | Daxor trades under DXR ticker. |
| When did Daxor go public? | Daxor went public in 1983. |
| Who are competitors of Daxor? | Daxor main competitors include Pentixapharm Holding, Sensus Healthcare, Tobii, HeartBeam, Pangaea Oncology, SMAIO, BATM Advanced Communications, Pulmonx, Gentian Diagnostics, Xtant Medical. |
| What is the current market cap of Daxor? | Daxor's current market cap is $61M. |
| What is the current revenue of Daxor? | Daxor's last 12 months revenue is $9M. |
| What is the current revenue growth of Daxor? | Daxor revenue growth (NTM/LTM) is 76%. |
| What is the current EV/Revenue multiple of Daxor? | Current revenue multiple of Daxor is 7.1x. |
| Is Daxor profitable? | No, Daxor is not profitable. |
| What is the current net income of Daxor? | Daxor's last 12 months net income is ($633K). |
| How many companies Daxor has acquired to date? | Daxor hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Daxor has invested to date? | Daxor hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Daxor
Lists including Daxor
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.